摘要
国内外权威指南推荐奈玛特韦片/利托那韦片用于治疗成人伴有进展为重症高风险因素的轻至中度新型冠状病毒感染(COVID-19)患者,能减少住院风险和死亡率。心血管疾病是轻中度COVID-19进展为重症/危重症的高风险因素之一,奈玛特韦片/利托那韦片常需和心血管药物同时使用。本文分析1例COVID-19伴心血管疾病患者所用的降血脂、抗血小板、降血压和抗凝等常用药物与奈玛特韦片/利托那韦片间的药物相互作用,以期为临床安全使用奈玛特韦片/利托那韦片提供药学专业参考。
National and international authoritative guidelines recommend that nirmatrelvir/ritonavir is indicated for the treatment of adults with mild-to-moderate COVID-19 at a high risk of progression to severe infection.The drug can reduce the risk of hospitalization and mortality.Cardiovascular disease is one of the high-risk factors for mild-to-moderate COVID-19patients progressing to severe/critical infection.Nirmatrelvir/ritonavir is often combined with cardiovascular drugs.We analyzed the drug interation of anticholesteremic agents,antiplatelet drugs,antihypertensive drugs and anticoagulant drugs used in a COVID-19 patient in the paper.It provides pharmaceutical reference for the safe use of nirmatrelvir/ritonavir in clinical practice.
作者
李玲玲
牛子冉
刘佳宁
田欣
梅丹
胡扬
LI Ling-ling;NIU Zi-ran;LIU Jia-ning;TIAN Xin;MEI Dan;HU Yang(Department of Pharmaey,Tangshan Gongren Hospital,Hebei Tangshan 063000,China;Deparment of Pharmacy,Peking Union Medical College Hospital,Chinese Acudemy of Medical Sciences,Bejing 100730,China;School of Truditional Chinese Medicine,Tianjin Unirersity of Trditional Chinese Medicine,Tianjin 301617,China)
出处
《临床药物治疗杂志》
2023年第1期32-35,共4页
Clinical Medication Journal
基金
北京协和医院中央高水平医院临床科研专项(2022-PUMCH-B-058)。
